Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 3/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250600 | 0.94 | TNK2 (0.43) | TNK2CXCR1ACHEALOX5LSS | |
| SCHEMBL6507888 | 0.89 | TNK2 (0.42) | TNK2CXCR1ACHELSSTLR7 | |
| SCHEMBL6246178 | 0.89 | TNK2 (0.42) | TNK2CXCR1ACHEALOX5LSS | |
| SCHEMBL6247182 | 0.89 | TNK2 (0.43) | TNK2CXCR1TLR7AURKAAURKB | |
| SCHEMBL6245061 | 0.89 | TNK2 (0.41) | TNK2CXCR1ACHEALOX5LSS | |
| SCHEMBL6244935 | 0.86 | PDE3B (0.45) | TNK2CHEK2KDM4EALDH1A1 | |
| Demeton S SCHEMBL6243668 | 0.84 | TNK2 (0.37) | TNK2CXCR1ACHEALOX5BRAF | |
| SCHEMBL6220994 | 0.82 | LSS (0.52) | TNK2CXCR1ACHELSSAURKA | |
| SCHEMBL6218299 | 0.81 | AURKA (0.46) | TNK2CXCR1ACHEALOX5LSS | |
| SCHEMBL6245037 | 0.80 | TNK2 (0.41) | TNK2ACHEALOX5LSSTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215582-A1 | Substituted pyrrolopyridines | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | claimed |
| US-20050215582-A1 | Substituted pyrrolopyridines | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215582-A1 | Substituted pyrrolopyridines | ITK, WEE1, PDPK1 | TNK2 110/4885CXCR1 3168/4885ACHE 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.